Medartis Appoints New CFO Amid Strategic Growth Phase

Medartis Holding AG ( (CH:MED) ) has provided an update.

Medartis Holding AG has announced the appointment of Dr. Peter Hackel as the new Chief Financial Officer, effective January 1, 2026. This leadership change comes at a strategic time as the company capitalizes on recent acquisitions in endoprosthetics and value implants, aiming to strengthen its position in the orthopedic industry. Dr. Hackel brings extensive financial and leadership experience from various industries, which is expected to support Medartis’ growth and operational continuity. The outgoing CFO, Dr. Dirk Kirsten, will ensure a smooth transition, having significantly contributed to the company’s transformation into a multi-brand organization with global reach.

The most recent analyst rating on (CH:MED) stock is a Hold with a CHF77.00 price target. To see the full list of analyst forecasts on Medartis Holding AG stock, see the CH:MED Stock Forecast page.

More about Medartis Holding AG

Medartis Holding AG, founded in 1997 and headquartered in Basel, Switzerland, is a leading global manufacturer and provider of medical devices for surgical fixation of bone fractures and joint replacements, focusing on the upper and lower extremities and the cranio-maxillofacial area. The company operates production facilities in the United States, Switzerland, Brazil, and France, employs around 1,400 people across 13 locations, and distributes its products in over 50 countries worldwide.

Average Trading Volume: 7,514

Technical Sentiment Signal: Hold

Current Market Cap: CHF1.04B

For an in-depth examination of MED stock, go to TipRanks’ Overview page.